In the contemporary era, cancer immunotherapy, which blocks the programmed cell death-1 (PD-1)/programmed death-ligand 1 (PD-L1) axis, is a novel treatment approach in a variety of malignancies. This evidence concerns the gene PDCD1 and cancer.